'Don't eat me' upstart taps Takeda vet on path to the clinic; Greg Mayes leaves Antios for Canadian psychedelics player
Nenad Grmusa was “really happy” at Takeda, where he’d been for more than a decade in various R&D strategy and finance positions. However, the more he learned about DEM BioPharma, the more intrigued he became by cancer’s unexplored “don’t eat me” signals.
Jonathan Weissman and team launched the aptly-named biotech back in June to deploy macrophages and other myeloid effector cells against tumors by using so-called “don’t eat me” and “eat me” signals, which allow cancer cells to evade the immune system.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.